Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARMA: Ketone Monitoring Approaches for DKA Risk Mitigation in T1D on SGLT2 Inhibitors
NCT07421518Phase 2Not yet recruiting
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Jun 2026
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of sotagliflozin in type 1 diabetes mellitus (T1D), sponsored by AdventHealth Translational Research Institute. Primary endpoint: Ketone events with Beta-hydroxybutyrate (BOHB) >1.5 mmol/L at 6 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sotagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07421518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421518.